@article{57ff3dfef0aa48cdaaf537331f810ca7,
title = "Heterozygous Tumor Suppressor Microenvironment in Cancer Development",
abstract = "Hereditary cancer syndromes are typically caused by mutations of a tumor suppressor gene that lead to the early development of multifocal benign neoplasms followed by their malignant progression. However, the term {\textquoteleft}hereditary cancer syndrome{\textquoteright} may be misleading, as a large subgroup of syndromes are characterized by highly penetrant benign tumors. The reason why these cardinal tumors rarely progress to malignancy has been an elusive question in cancer biology. In this opinion article, we propose a framework where a heterozygous tumor suppressor gene microenvironment has antagonistic roles in tumorigenesis, by accelerating development of benign tumors while restraining further progression to malignant cancers.",
keywords = "MPNST, NF1, STK11, benign tumor, hereditary benign tumor syndromes, hereditary cancer, malignant peripheral nerve sheath tumor, neurofibroma, tumor microenvironment, tumor suppressor gene",
author = "Brosseau, {Jean Philippe} and Le, {Lu Q.}",
note = "Funding Information: J.P.B. is a recipient of the Young Investigator Award from the Children{\textquoteright}s Tumor Foundation and the Early Investigator Research Award from the US Department of Defense. L.Q.L. holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund, the Thomas L. Shields, M.D. Professorship in Dermatology, and is supported by funding from the National Cancer Institute of the National Institutes of Health (grant number R01 CA166593 and U54 CA 196519 ) and the US Department of Defense . Funding Information: J.P.B. is a recipient of the Young Investigator Award from the Children's Tumor Foundation and the Early Investigator Research Award from the US Department of Defense. L.Q.L. holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund, the Thomas L. Shields, M.D. Professorship in Dermatology, and is supported by funding from the National Cancer Institute of the National Institutes of Health (grant number R01 CA166593 and U54 CA 196519) and the US Department of Defense. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = sep,
doi = "10.1016/j.trecan.2019.07.004",
language = "English (US)",
volume = "5",
pages = "541--546",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
number = "9",
}